Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, November 22, 2023
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
[ Wed, Nov 22nd 2023
] - WOPRAI
Tue, November 21, 2023
[ Tue, Nov 21st 2023
] - WOPRAI
[ Tue, Nov 21st 2023
] - WOPRAI
[ Tue, Nov 21st 2023
] - WOPRAI
[ Tue, Nov 21st 2023
] - WOPRAI
[ Tue, Nov 21st 2023
] - WOPRAI
[ Tue, Nov 21st 2023
] - WOPRAI
[ Tue, Nov 21st 2023
] - WOPRAI
[ Tue, Nov 21st 2023
] - WOPRAI
[ Tue, Nov 21st 2023
] - WOPRAI
[ Tue, Nov 21st 2023
] - WOPRAI
[ Tue, Nov 21st 2023
] - WOPRAI
Brian Abrahams Reiterated (SRPT) at Buy and Held Target at $148 on, Nov 21st, 2023
Brian Abrahams of RBC Capital, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $148 on, Nov 21st, 2023.
Brian has made no other calls on SRPT in the last 4 months.
There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 1 agrees with Brian's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Kristen Kluska of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $80 on, Thursday, November 2nd, 2023
These are the ratings of the 5 analyists that currently disagree with Brian
- Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $141 on, Thursday, November 2nd, 2023
- Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $93 on, Thursday, November 2nd, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $146 on, Tuesday, October 31st, 2023
- Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $115 on, Tuesday, October 31st, 2023
- Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $160 on, Tuesday, September 26th, 2023
